Moderna Stands Alone With Single-Antigen Approach To COVID-19 Vaccine

Targeting SARS-CoV-2 Spike Protein Is Sensible, Analyst Says

 
• By Joseph Haas
microbiologist with a tube of biological sample contaminated by Coronavirus with label Covid-19 / doctor in the laboratory with a biological tube for analysis and sampling of Covid-19 infectious disea
Moderna likely will require manufacturing partners if its COVID-19 is viable

More from Clinical Trials

More from R&D